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Introduction {#sec1}
============

A wealth of studies using bone-derived mesenchymal stromal cells (MSCs) has revealed their importance for engineering to repair cartilage and bone tissues, and for ameliorating hematopoietic disorders ([@bib4]). However, it is still not firmly established whether MSC populations encompass mesenchymal progenitor and/or stem cells. In a recent review, [@bib5] proposes that MSCs, rather than being progenitor/stem cells, home to sites of injury and secrete factors that induce regeneration by resident stem cells. As it is indeed difficult to expand MSCs in culture without affecting their initial characteristics ([@bib4], [@bib22]), the prospective isolation and direct analysis of primary mesenchymal progenitors from human bone marrow and mouse long bones is central to identify their origins and assessing their multi-lineage differentiation potential. Since the first isolation of clonogenic mesenchymal progenitors from human bone marrow ([@bib34]), lineage tracing and prospective characterization using mouse models has identified different types of mesenchymal progenitor/stem cells and provided fundamental insights into their functions during normal bone homeostasis and repair ([@bib26], [@bib29]). However, the relatedness of these different mesenchymal populations from mice and their corresponding human orthologs remains uncertain.

Studying mouse limb development provides insight into the ontology and functions of the mesenchymal progenitors that orchestrate development of long bones (reviewed by [@bib21]). In brief, the development of the skeletal primordia in early mouse limb buds is initiated by the condensation of multipotent mesenchymal progenitors at around embryonic day 10.5 (E10.5) and their commitment as *Sox9*-expressing osteo-chondrogenic progenitors ([@bib2]), which will form the cartilage primordia. The SOX9-positive cells differentiate into proliferating chondrocytes while peripheral mesenchymal cells will form the perichondrium ([@bib3]). Endochondral ossification is initiated after chondrocytes become hypertrophic (∼E12.5), which involves differentiation of perichondrium progenitors into *Osterix* (*Osx*) expressing osteoblastic and mesenchymal progenitors ([@bib19], [@bib23], [@bib24], [@bib30]). Limb long bone growth and bone marrow formation depends on angiogenesis, which is triggered by vascular endothelial growth factor (VEGF)-mediated attraction of endothelial and hematopoietic progenitors (≥E14.5; [@bib26]). The main migration of hematopoietic stem cells (HSCs) from the fetal liver to the bone marrow initiates perinatally, peaks immediately after birth, and continues until puberty, after which bone homeostasis is achieved ([@bib17], [@bib41]). Concurrently, the cellular composition of the mesenchymal stromal compartment changes to support hematopoiesis ([@bib13], [@bib23], [@bib24]). Marking of *Col2a* expressing cells in mouse embryos at E13.5 shows that these cells are retained in the epiphysis and metaphysis of long bones for up to 1 year after birth ([@bib31]). Marking *Osx*-expressing cells at E14.5 allows detection of labeled descendants in the diaphysis of even older mice ([@bib19]), which is not the case if *Osx*-positive hypertrophic chondrocytes are marked one day earlier (E13.5; [@bib23], [@bib30]). In addition to hypertrophic chondrocytes and early osteoblasts, *Osx* is expressed in mesenchymal progenitors of the developing bone marrow up to early postnatal stages (through postnatal day 3 \[P3\]; [@bib24], [@bib31]). These and other studies suggest that there are different checkpoints during the endochondral ossification program that dictate the induction or reprogramming of new types of mesenchymal progenitors *in situ* or from nearby tissues.

Prospective isolation by flow cytometry detecting specific signatures of cell-surface molecules allowed identification of distinct mesenchymal and skeletal progenitor populations. Among these is a rare population of cells isolated by enzymatic digestion of compact bone and referred to as PαS cells (CD45^neg^ TER119^neg^ **P**DGFR**α**^pos^ **S**CA-1^pos^; [@bib25]). PαS cells are quiescent cells located in the perivascular space close to the endosteum. They display the highest fibroblast colony-forming units (CFU-F) capacity among the different mesenchymal progenitor populations isolated from mice and possess a robust tri-lineage differentiation potential ([@bib25], [@bib45]). In mice, PαS cells give rise to osteoblasts, are able to maintain long-term HSCs, and home back to bone marrow following intravenous injection ([@bib7], [@bib13], [@bib15], [@bib25], [@bib32]). PαS cells express *Mx1* but are not part of the cell populations marked in *Col2a* and *Osx* lineage-tracing experiments ([@bib31], [@bib32]). More recently, CD200^pos^CD51^pos^ mesenchymal progenitors (lacking CD90, CD105, and 6C3) were isolated as a mesenchymal population able to give rise to cartilage and bone. These multipotent cells were termed mouse skeletal stem cells (mSSCs) and are able to support hematopoiesis *in vivo* ([@bib8]). Finally, analysis of bone marrow stromal cells from human fetuses identified a mesenchymal cell population expressing platelet-derived growth factor receptor α (PDGFRα) and CD51 (PαCD51 cells), which is also able to self-renew and support expansion of HSCs ([@bib33]).

As it is not clear when these different mesenchymal progenitor cells arise and to what extent they are ontogenetically related, we used their characteristic CD signatures for flow-cytometric analysis of the stromal compartment of limb buds and long bones from mouse embryonic and postnatal stages. We show that murine PαS cells and mSSCs, which arise among the PαCD51-positive mesenchymal cells in early limb buds, constitute two distinct cell populations in developing and adult long bones. PαS cells can be subdivided into four subpopulations using CD73 and CD90, which mark chondrogenic and osteogenic lineages, respectively ([@bib8], [@bib11], [@bib27], [@bib43]). PαS cells are already detected during formation of the cartilage anlagen in early limb buds and are most abundant in newborn mice. We also determined the bone-forming capacity of cartilage engineered from CD90^pos^, CD90^neg^ and parental PαS cells following subcutaneous implantation. The CD90^pos^ PαS scaffolds are efficiently remodeled into bone organoids (for a definition of bone organoids see [@bib4]), which contain a well-structured marrow consisting of mesenchymal progenitors and host-derived endothelial and hematopoietic compartments.

Results {#sec2}
=======

Ontogenic Identification and Relatedness of Limb Bud and Long Bone Mesenchymal Cell Populations with PαCD51 and PαS Signatures {#sec2.1}
------------------------------------------------------------------------------------------------------------------------------

Mouse limb buds and developing long bones were analyzed at different embryonic, fetal, and postnatal time points to identify mesenchymal cells with signatures of different MSC populations. Following preparation of single-cell suspensions, dead cells, endothelial, hematopoietic, and epithelial/ectodermal cells were first removed using the appropriate cell-surface markers (see [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}). An ontogenetic flow-cytometric analysis was done using the remaining so-called lineage-negative (Lin^neg^) cells from the different stages ([Figures 1](#fig1){ref-type="fig"} and [2](#fig2){ref-type="fig"}). Initially, the signatures of two types of MSC, namely PαCD51 and PαS progenitors, were profiled ([Figure 1](#fig1){ref-type="fig"}). In developing mouse limb buds (E10.5 and E14.5--15.5), the vast majority of Lin^neg^ mesenchymal progenitors are PαCD51 positive (∼80%--95%, [Figures 1](#fig1){ref-type="fig"}A and 1E). During fetal long bone development (E14.5--18.5), PαCD51-positive cells (also including osteoblasts; [@bib10]) remain most prominent ([Figure 1](#fig1){ref-type="fig"}E, purple bars). During early postnatal development (P1--3), PαCD51 cells account for ∼50% of the Lin^neg^ cells, but their frequency drops to ∼4% in juvenile and adult long bones. This decrease in PαCD51 cells is paralleled by a significant increase in PDGFRα single-positive (Pα) cells after birth ([Figures 1](#fig1){ref-type="fig"}A and 1E).Figure 1Ontogenic Identification of Mesenchymal Stromal Cells during Embryonic, Fetal, and Postnatal Limb Bud and Long Bone Development(A--D) Cells isolated from total limb buds at embryonic day 10.5 (E10.5), long bones at E14.5--15.5, E18.5, postnatal days 1--3 (P1--3), week 4 (W4; juvenile stage), and W10--13 (adult stages) were analyzed by flow cytometry. The analysis was done from forelimb buds at E10.5 and hindlimb long bones at all subsequent stages. Red cell lysis was included for older stages (≥W4). The lineage marker pool (Lin) includes the following antigens: CD45, TER119, CD31, Gr1, and CD11b (all stages) plus EpCAM and CD309 (only for limb buds). Dead cells were gated out using 7AAD. Results are shown as pseudo-color plot representations of the subsequent analysis of the lineage-negative (Lin^neg^) fraction. (A and B) Distribution of Lin^neg^ cells expressing either the platelet-derived growth factor receptor α (PDGFRα)/CD51 or PDGFRα/SCA-1 antigens. Note that in limb buds at E10.5, CD51 is assessed against SCA-1 (B, see text). (C) Overlapping dot plot representations show that PαS cells (blue) are mostly contained in the PαCD51 population (gray). (D) Fraction of the SCA-1-positive PαCD51 cells corresponding to PαS cells.(E) Percentage of PαCD51- and Pα-positive cells in the Lin^neg^ population. Per stage n ≥ 3 independent experiments were analyzed. All results are presented as averages ± SD.Figure 2Ontogenic Analysis of Cells with mSSC and PαS SignaturesFlow-cytometric identification of different mesenchymal cell types in the Lin^neg^ fraction isolated from limb buds (E10.5--14.5) and limb long bones (E18.5--W12) of *Sox9*-GFP mice.(A) Pseudo-color plot distribution of CD51- and SCA-1 positive Lin^neg^ cells. Note that the PαS cells are almost completely contained within the CD51^pos^SCA-1^pos^ cell population.(B) Analysis of CD51^pos^ Lin^neg^ cells with CD200 and SCA-1 shows that the CD200^pos^ (including mSSC) and SCA-1^pos^ cells (including PαS) define distinct cell populations at all stages.(C) Additional flow-cytometric analysis identifies mSSCs as CD90^neg^CD105^neg^6C3^neg^ subpopulation within the CD51^pos^CD200^pos^ fraction (percentage indicated within the yellow-green frame). Note that a significant fraction of mSSCs expresses *Sox9*-GFP from E13.5 and in particular from W4 onward.(D) Variable expression of *Sox9*-GFP and the CD90, CD105, and 6C3 antigens in PαS cells.(E) Graph showing the percentage of PαS cells and mSSCs in the Lin^neg^ CD51^pos^ population. Per time point and cell type n ≥ 3 independent experiments were analyzed. All results are presented as averages ± SD. Unpaired 2-tailed Student's t test was used to assess significance. ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001 were considered statistically significant.

In contrast to the predominant PαCD51 population, PαS cells are less abundant ([Figure 1](#fig1){ref-type="fig"}B). In early limb buds (E10.5), SCA-1-positive mesenchymal progenitors express CD51 and intermediate levels of PDGFRα ([Figures 1](#fig1){ref-type="fig"}B--1D). From E14.5 onward, the PαS population increases progressively ([Figure 1](#fig1){ref-type="fig"}C) such that the highest proportion is observed around birth (∼30% at E18.5 and P1--3, [Figure 1](#fig1){ref-type="fig"}B). This analysis ([Figure 1](#fig1){ref-type="fig"}) establishes that the PαCD51-positive cells encompass the PαS population at all stages. This is relevant to potential therapeutic applications as, in contrast to CD51, the SCA-1 antigen is not present in humans ([@bib18]).

PαS and mSSC Signatures Identify Two Distinct Progenitor Populations within the PαCD51 Mesenchymal Cell Pool {#sec2.2}
------------------------------------------------------------------------------------------------------------

We next analyzed the relationship between mSSC (CD51^pos^CD200^pos^ CD90^neg^CD105^neg^ 6C3^neg^ cells; [@bib8]), PαCD51, and PαS populations ([Figure 2](#fig2){ref-type="fig"}). Within the Lin^neg^ cells, CD51 is key to defining the predominant PαCD51 population and SCA-1 identifies the PαS cells within this population ([Figure 2](#fig2){ref-type="fig"}A). In addition, the distribution of SCA-1- and CD200-positive cells within Lin^neg^CD51^pos^ cell pool was determined ([Figure 2](#fig2){ref-type="fig"}B). Strikingly, this analysis establishes that the SCA-1^pos^ PαS cells and CD200^pos^ mSSCs segregate as mutually exclusive populations at all stages ([Figure 2](#fig2){ref-type="fig"}B). In early mouse limb buds (E10.5), the CD51^pos^SCA-1^pos^ PαS cells are much more abundant than CD51^pos^CD200^pos^ cells (5% versus 0.5%; [Figures 2](#fig2){ref-type="fig"}A, 2B, and 2E). During fetal and early postnatal long bone development (E14.5--P2), PαS cells prevail over mSSCs ([Figure 2](#fig2){ref-type="fig"}E). During peak bone angiogenesis and invasion of HSCs into long bones immediately after birth ([@bib41]), PαS cells account for about half of all PαCD51 cells. During puberty around week 4 (W4), mSSCs are about twice as frequent as PαS cells, while these populations are similarly represented in adult long bones ([Figures 2](#fig2){ref-type="fig"}B and 2E).

To gain insight into the potential overlap of these two cell populations with *Sox9*-positive progenitors, we included the *Sox9*^*IRES-GFP*^ transgene in our analysis ([@bib9]). In early limb buds (E10.5), the *Sox9*-GFP-positive cells correspond mostly to osteo-chondroprogenitors ([@bib2] and our unpublished data). During subsequent development, *Sox9* is expressed by chondroblasts, reduced in proliferating chondrocytes, and re-expressed in pre-hypertrophic chondrocytes ([@bib1], [@bib12]). While *Sox9*-GFP levels are always low in PαS cells, the majority of mSSCs express intermediate to high levels of *Sox9* ([Figures 2](#fig2){ref-type="fig"}C and 2D).

As the *Prx1*-Cre transgene is expressed by most limb bud mesenchymal progenitors, we used it to activate a conditional GFP reporter (*β-ACTIN-loxP-stop-loxP-EGFP*; [@bib16], [@bib20]). This allowed us to determine the fractions of PαCD51, PαS, and mSSC populations in GFP-positive cells at P2 ([Figure S1](#mmc1){ref-type="supplementary-material"}). This analysis revealed that all GFP-positive cells are contained in the PαCD51 population, which in turn shows that all PαS cells and mSSCs are GFP positive, i.e., are either *Prx1*-expressing cells or their descendants. In contrast the Pα cells, which become predominant during postnatal development, are GFP negative ([Figure S1](#mmc1){ref-type="supplementary-material"}). This analysis establishes PαCD51-positive cells as the major cell population within the mesenchymal (stromal) compartment during embryonic limb bud and fetal long bone development.

Next, the different mesenchymal populations in long bones after birth (P1--3) and during adult bone homeostasis (W10--13) ([Figure 3](#fig3){ref-type="fig"}) were analyzed for the expression of key genes relevant to chondrogenesis, osteogenesis, and hematopoiesis (*Prx1*, *Col2a1*, and *Mmp13*; *Osx*, *Lepr*, and *Cxcl12*, respectively). qRT-PCR analysis of the different mesenchymal populations ([Figure 3](#fig3){ref-type="fig"}A) showed that the different cell populations express distinct levels of these genes in a rather consistent manner when comparing newborn and adult mice. The most prominent Lin^neg^ population in adults, Pα cells ([Figure 1](#fig1){ref-type="fig"}B), express none of these genes at birth and very variable levels of *Lepr* in adults ([Figures 3](#fig3){ref-type="fig"}B and 3C). Therefore, Pα cells are unlikely to possess robust chondrogenic and osteogenic differentiation potential. PαCD51 cells, PαS cells, and mSSCs express *Prx1* at birth and in adults. While PαS cells do not express chondrogenic and osteogenic markers, they express the highest levels of *Prx1* and low to intermediate levels of *Cxcl12* and *Lepr* at both stages ([Figures 3](#fig3){ref-type="fig"}B and 3C). This expression pattern points to the likely immature nature of PαS cells and is in agreement with their potential to support HSCs (see below). mSSCs isolated from adult long bones express high levels of *Col2a1*, *Mmp13*, and, notably, *Osx* ([Figure 3](#fig3){ref-type="fig"}C), which corroborates their osteo-chondrogenic potential ([@bib8]). Finally, SCA-1^neg^CD200^neg^ PαCD51 (PαCD51DN) cells express the highest levels of *Cxcl12* and *Lepr* while all other genes are expressed at only low to intermediate levels. These results indicate that the PαCD51DN population could encompass CAR cells (CXCL12-abundant reticular cells), which support B cell development ([@bib13], [@bib28], [@bib39]). Taken together, this analysis of few selected key genes corroborates the distinct nature of the different mesenchymal stromal progenitor populations identified by flow cytometry.Figure 3Differential Expression of Markers for Distinct Cell Lineages in the Isolated Mesenchymal Cell Populations(A) Sorting strategy for the cells of interest isolated from hindlimb long bones (right). The color code for gates of the different populations is also the same for (B) and (C).(B and C) qRT-PCR analysis of marker genes for different mesenchymal subpopulations in newborn (B) and adult mice (C). *Prx1* is expressed by limb mesenchymal progenitors; *Col2a1* by chondroblasts and primitive osteogenic progenitors; *Mmp13* by hypertrophic chondrocytes; *Osx* by pre- and hypertrophic chondrocytes, early osteoblasts, and MSC. *Cxcl-12* and *Lepr* mark mesenchymal progenitors and MSC in the bone marrow. Expression levels are shown relative to the expression in PαCD51 cells. n ≥ 4 independent experiments were analyzed per cell population. All results are presented as averages ± SD. Unpaired 2-tailed Student's t test was used to assess significance. ^∗^p ≤ 0.05, ^∗∗^p ≤ 0.01 were considered statistically significant.

PαS Cells Are a Heterogeneous Population Consisting of Subpopulations with Distinct CD Signatures {#sec2.3}
-------------------------------------------------------------------------------------------------

The PαS population was analyzed in more detail, as these cells are detected from early limb bud stages onward (see above). We performed the same analysis as shown in [Figures 1](#fig1){ref-type="fig"} and [2](#fig2){ref-type="fig"} but also assessing the expression of CD73 and CD90 ([Figure 4](#fig4){ref-type="fig"}). CD73 is expressed by chondrocyte progenitors and CD90 marks the osteogenic lineage (see [Introduction](#sec1){ref-type="sec"}). Analysis of these two markers using freshly isolated adult PαS cells identifies four distinct subpopulations either negative or positive for CD90 and expressing intermediate (im) or high (hi) levels of CD73 (CD90^neg^CD73^im^, CD90^neg^CD73^hi^, and CD90^pos^CD73^im^, CD90^pos^CD73^hi^; [Figure 4](#fig4){ref-type="fig"}A). *In vitro* expansion of PαS cells causes a shift in the abundance of the four subpopulations. After two passages, the fractions of the two CD90^neg^ subpopulations are much reduced, while the CD90^pos^ PαS subpopulations become predominant ([Figure 4](#fig4){ref-type="fig"}B). This reduction is paralleled by a decrease in the multipotency, which affects mostly the osteo-chondrogenic differentiation potential (data not shown).Figure 4The PαS Populations Consist of Four Subpopulations Defined by Differential CD73 and CD90 Expression(A) Flow-cytometric analysis of the expression of CD73 and CD90 in freshly isolated PαS cells from adult hindlimb long bones (W8--12).(B) Reanalysis of CD73 and CD90 subpopulations in PαS cells that have been expanded for two passages in culture.The rightmost panels show averages ± SD for n ≥ 8 independent experiments per dataset.

To understand when these four PαS subpopulations arise during limb long bone development, we analyzed Lin^neg^ cells isolated from *Sox9*-GFP expressing embryos and mice by flow cytometry ([Figure 5](#fig5){ref-type="fig"}). During embryonic, fetal, and early postnatal stages, the *Sox9*-GFP-positive cells that mark the osteo-chondrogenic lineage ([Figure 5](#fig5){ref-type="fig"}A) comprise a significant fraction of all Lin^neg^ mesenchymal (stromal) cells ([Figure 5](#fig5){ref-type="fig"}E). From about 2 weeks postnatally, the fraction of *Sox9*-GFP cells within the Lin^neg^ fraction decreases significantly ([Figures 5](#fig5){ref-type="fig"}A and 5E). Concurrently, there is a switch in the proportions of the CD90^neg^ and CD90^pos^ PαS subpopulations ([Figures 5](#fig5){ref-type="fig"}E and 5F).Figure 5Developmental Origin of the PαS Subpopulations(A--D) Flow-cytometric analysis of Lin^neg^ cells isolated from limb buds and long bones of *Sox9-*GFP mice. (A) Expression of *Sox9*-GFP in comparison with PDGFRα levels (gating frame indicates GFP-positive cells). (B) PαS cells are indicated by the gating frame in blue. (C) Contour plot analysis of PαS cells in combination with CD90 and CD73 reveals that the four subpopulations arise progressively during long bone development. (D) Overlap of PαS cells (turquoise) with *Sox9*-GFP-positive cells (gray, from A). The gating frame shows the fraction (%) of *Sox9*-expressing PαS cells.(E) Percentage of *Sox9*-GFP-positive cells in the Lin^neg^ population.(F) Percentage of CD90^neg^ (white bars) and CD90^pos^ (gray bars) cells in the PαS populations.(G) Numbers of PαS isolated from two limb buds or hindlimb long bones per embryo or mouse shows that PαS cells are most abundant in newborn mice.All results shown are representative of n ≥ 3 independent experiments per stage. All results are presented as averages ± SD in (E--G).

Mesenchymal SCA-1^pos^ cells in early limb buds express CD51 and intermediate levels of PDGFRα (E10.5; [Figure 5](#fig5){ref-type="fig"}B, compare with [Figures 1](#fig1){ref-type="fig"} and [2](#fig2){ref-type="fig"}). At this stage, *Sca-1* is expressed by the undifferentiated mesenchymal progenitors located distally and close to the limb bud ectoderm ([Figure S2](#mmc1){ref-type="supplementary-material"}A; [@bib40]). Furthermore, PαS cells express intermediate levels of CD73 (CD73^im^) while CD90 is not detected (E10.5; [Figures 5](#fig5){ref-type="fig"}B, 5C, and [S2](#mmc1){ref-type="supplementary-material"}B). The PαS progenitors are a heterogeneous population, as 10%--15% of them are also *Sox9*-GFP positive in early limb buds ([Figure 5](#fig5){ref-type="fig"}D). In fact, the majority of *Sox9*-GFP-positive progenitors in the stromal fraction correspond to osteo-chondrogenic progenitors that also express CD73 ([Figure S2](#mmc1){ref-type="supplementary-material"}B). During the onset of endochondral ossification (E14.5--15.5), the four PαS subpopulations detected in adult long bones become apparent ([Figures 5](#fig5){ref-type="fig"}C and 5F, compare with [Figure 4](#fig4){ref-type="fig"}A). Already at this early stage, PαS cells are detected in the developing perichondrium ([Figure S2](#mmc1){ref-type="supplementary-material"}C). Around birth (E18.5 and P2), the CD90^neg^CD73^hi^ PαS subpopulation is most abundant ([Figures 5](#fig5){ref-type="fig"}C and 5F). From W4 onward, the two CD90^pos^ PαS subpopulations become most prominent as they increase to ∼75% of all PαS ([Figures 5](#fig5){ref-type="fig"}C and 5F). The maximum numbers of PαS cells can be isolated from mouse long bones at early postnatal stages (P1--4: ∼12--20 × 10^3^ cells), while their numbers decrease progressively thereafter (≤6.5 × 10^3^ cells in adult mice, [Figure 5](#fig5){ref-type="fig"}G). Furthermore, the fraction of *Sox9*-GFP-positive cells remains rather constant in all four PαS subpopulations during fetal long bone development, but increases to ∼70% by puberty around W4 ([Figure 5](#fig5){ref-type="fig"}D).

*In Vitro* Tri-lineage Differentiation Potential of the Four PαS Subpopulations {#sec2.4}
-------------------------------------------------------------------------------

As PαS cells are most prominent at P2 ([Figure 5](#fig5){ref-type="fig"}G) and the chondrogenic and osteogenic programs are both active, the four subpopulations were isolated from limb long bones to assess their *in vitro* clonogenic and tri-lineage differentiation potential ([Figures S3](#mmc1){ref-type="supplementary-material"} and [6](#fig6){ref-type="fig"}). Clonal analysis establishes that the clonogenic potential of the two CD90^pos^ subpopulations is ∼2-fold higher than one of the CD90^neg^ PαS subpopulations ([Figure S3](#mmc1){ref-type="supplementary-material"}A). However, cell clones derived from all four PαS subpopulations undergo proliferation arrest during *in vitro* expansion ([Figure S3](#mmc1){ref-type="supplementary-material"}B and data not shown), which precludes generation of sufficient cells for tri-lineage differentiation analysis. Therefore, equal numbers of freshly isolated cells from all four PαS subpopulations were only briefly expanded prior to inducing differentiation into chondrogenic, osteogenic, and adipogenic cells (tri-lineage differentiation, [Figure 6](#fig6){ref-type="fig"}; for details see [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}).Figure 6*In Vitro* Tri-lineage Differentiation Potential of the PαS SubpopulationsThe four PαS subpopulations were sorted from hindlimb long bones of newborn mice (P2). Cells were briefly expanded and chondrogenic, osteogenic, and adipogenic differentiation using equal numbers of cells from all PαS subpopulations were induced in the appropriate differentiation media. Controls were maintained in expansion medium (see [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}).(A) Chondrogenic differentiation was assayed after 5 days: (i) *Sox9* and *Col2a1* transcript levels and (ii) the distribution of SOX9 and collagen type 2 (COL2) proteins are shown.(B) Osteogenic differentiation was assayed after 21 days. (i) *Osterix* (*Osx*) and *Osteocalcin* (*Oc*) transcript levels. (ii) The extent of mineralization was detected by Alizarin red staining and the OSX protein distribution analyzed by immunofluorescence.(C) Adipogenic differentiation was analyzed molecularly after 5 days. (i) *Pparγ2* and *Fabp4* transcript levels (marking pre-adipocytes and adipocytes). (ii) The peroxisome proliferator-activated receptor γ (PPARγ) protein distribution was analyzed by immunofluorescence. Lipid droplets were revealed by Nile red staining after 10 days of differentiation.Transcript levels were normalized to *Rpl-19* transcripts. Nuclei were counterstained with DAPI (blue). n ≥ 2 independent experiments were analyzed per data point and yielded identical results. Results in (i) are presented as averages ± SD. Scale bars, 100 μm.

Culturing cells in chondrogenic differentiation medium results in upregulation of *Sox9* and *Col2a* expression in all four PαS subpopulations ([Figure 6](#fig6){ref-type="fig"}A). However, the *Sox9* and *Col2a* expression levels are much higher in the two CD90^neg^ PαS subpopulations (CD90^neg^CD73^int^ and CD90^neg^CD73^hi^, [Figure 6](#fig6){ref-type="fig"}A). In agreement, the two CD90^neg^ cell populations display a much higher osteogenic and adipogenic differentiation potential than CD90^pos^ cells ([Figures 6](#fig6){ref-type="fig"}B and 6C). The *in vitro* tri-lineage differentiation potential of the two CD90^pos^ subpopulations (CD90^pos^CD73^hi^ and CD90^pos^CD73^int^) is lower, but it is important to note that these cells are able to initiate both chondrogenic and adipogenic differentiation programs as revealed by transcriptional upregulation of specific markers for these lineages ([Figures 6](#fig6){ref-type="fig"}A and 6C). In osteogenic culture conditions, the *Osx* and *Osteocalcin* (*Oc*) expression is upregulated in both CD90^pos^ subpopulations ([Figure 6](#fig6){ref-type="fig"}Bi), but no OSX protein and mineralization (visualized by Alizarin red staining) are detected ([Figure 6](#fig6){ref-type="fig"}Bii). These results indicate that while the CD90^neg^ PαS cells possess robust tri-lineage differentiation potential upon induction in culture, the CD90^pos^ PαS cells initiate differentiation along all three lineages but fail to undergo complete adipogenic and osteogenic differentiation in 2D cultures ([Figure 6](#fig6){ref-type="fig"}).

Cartilage Derived from CD90^pos^ PαS Cells Is Remodeled *In Vivo* into Bone Organoids Attracting Host-Derived Angiogenesis and Hematopoiesis {#sec2.5}
--------------------------------------------------------------------------------------------------------------------------------------------

The *in vivo* differentiation and endochondral-bone-forming potential of CD90^neg^ and CD90^pos^ PαS cells isolated from newborn mice was assayed by subcutaneous engraftment of engineered 3D cartilage tissue implanted into nude mice ([Figure 7](#fig7){ref-type="fig"}). These two rather than all four PαS subpopulations were assayed, as the respective *in vitro* differentiation of the two CD90^neg^ and two CD90^pos^ subpopulations is very similar ([Figure 6](#fig6){ref-type="fig"}). Following flow-cytometric isolation of parental PαS cells and its CD90^neg^ and CD90^pos^ subpopulations, cells were briefly expanded, seeded into collagen type 1 (COL1) matrices, and cultured in chondrogenic medium ([Figure 6](#fig6){ref-type="fig"}A, see [Experimental Procedures](#sec4){ref-type="sec"}). After 1 week, the cartilage scaffolds generated by the three different cell populations were either analyzed ([Figure 7](#fig7){ref-type="fig"}B) or implanted subcutaneously into athymic nude mice ([Figure 7](#fig7){ref-type="fig"}C).Figure 7*In Vitro* Chondrogenic and *In Vivo* Bone-Forming Potential of CD90^pos^ and CD90^neg^ PαS Subpopulations(A) Scheme showing the experimental setup for engraftment of cartilage constructs into nude mice. FACS, fluorescence-activated cell sorting; s.c., subcutaneous.(B) Total PαS and CD90^pos^ and CD90^neg^ PαS subpopulations were isolated from long bones of newborn mice. Following 1 week of expansion, the different cells were seeded into collagen type 1 (COL1) matrices and cultured for 1 week in chondrogenic differentiation medium (experimental samples) or expansion medium (controls). 3D cartilage constructs were analyzed for morphology (blue) and chondrogenesis by Safranin O (red staining), and the SOX9 (red) and COL2 (green) distribution determined by immunofluorescence. Scale bars, 100 μm.(C) 3D cartilage constructs were implanted subcutaneously into adult nude mice and retrieved 8 weeks later to assess morphology (blue) and cartilage by Safranin O red staining. Note the absence of cartilage in all samples. No ossicles developed in control implants (see B and data not shown). Frequencies of ossicles with bone structures: PαS constructs n = 5/5; CD90^pos^ PαS constructs n = 5/5; CD90^neg^ PαS constructs n = 2/5. Scale bars, 200 μm (see also [Figure S4](#mmc1){ref-type="supplementary-material"}).(D) Immunofluorescence analysis of the different constructs after 8 weeks *in vivo* differentiation to detect OSX-positive cells (red) and CD31-positive endothelial cells (green, indicative of angiogenesis). Sections were counterstained with DAPI (blue) to reveal nuclei. The enlarged regions 1 and 2 are shown in the right panels. Scale bars, 500 μm (low magnification) and 100 μm (high magnification).(E) Immunofluorescence analysis of ossicles retrieved after implanting DsRed-positive CD90^pos^ PαS cartilage constructs (8 weeks). Left panels show that the CD45-positive hematopoietic cells are host derived, as they are not expressing DsRed. Right panels show that the CD31-positive endothelial cells are also host derived. Scale bars, 100 μm (upper panels) and 10 μm (middle and lower panels).(F) Sections through the bone marrow of CD90^pos^PαS ossicles. Immunofluorescence analysis reveals Gr1-positive granulocytes and B220-positive cells (immature and mature B lymphocytes). Nuclei were counterstained with DAPI (blue). Scale bars, 100 μm (low magnification) and 10 μm (high magnification).(G) Co-localization of CD45 and SCA-1 (yellow) labels HSCs and multipotent progenitors. Co-expressing cells were observed near the endosteum (arrowhead in the left panel). Nuclei were stained with DAPI. Scale bars, 100 μm (low magnification) and 10 μm (high magnification).All results are representative of n ≥ 3 independent samples.

Safranin O staining of matrices and detection of the SOX9 and COL2 proteins after 2 weeks showed that all three cell populations are able to produce cartilage in COL1 matrices ([Figure 7](#fig7){ref-type="fig"}B). In particular, it appears that the chondrogenic differentiation potential of CD90^pos^ PαS cells is significantly enhanced by culturing them in 3D COL1 matrices ([Figure 7](#fig7){ref-type="fig"}B, compare with [Figure 6](#fig6){ref-type="fig"}Aii).

Eight weeks after subcutaneous implantation, the three types of scaffolds were explanted and histological analysis established that all cartilage tissues engineered from parental PαS cells and the CD90^pos^ PαS subpopulation had formed ossicles with bone marrow cavities (n = 5/5, [Figure 7](#fig7){ref-type="fig"}C). In contrast, bone formation by CD90^neg^ PαS-based constructs is less efficient, as small ossicles with a poorly developed bone marrow compartment formed in only two of the five implants ([Figure 7](#fig7){ref-type="fig"}C). The absence of glycosaminoglycans (normally stained in red by Safranin O) establishes that the cartilage extracellular matrix was not maintained *in vivo*. Indeed, neither COL2 nor Aggrecan were detected in the remodeled explants (data not shown). As a significant fraction of PαS cells comprises SOX9-positive cells ([Figure 5](#fig5){ref-type="fig"}D), we analyzed the SOX9 distribution in the explants by immunofluorescence ([Figure S4](#mmc1){ref-type="supplementary-material"}). Few scattered SOX9-positive cells are present in explants derived from PαS cells and CD90^pos^PαS chondrogenic scaffolds, while abundant SOX9-positive cells remain in CD90^neg^ PαS explants ([Figure S4](#mmc1){ref-type="supplementary-material"}). In fact, this analysis showed that cartilage was not maintained in any of the constructs generated using the three different cell populations. This is likely due to the fact that the milieu of the host does not support cartilage maintenance, which depends on inhibition of VEGF signaling ([@bib8]).

The distribution of CD31-positive endothelial and OSX-positive cells ([@bib23], [@bib30]) was analyzed on sections to gain insight into the extent to which the endochondral ossification had processed ([Figure 7](#fig7){ref-type="fig"}D). Cells expressing these markers are abundant in both PαS cells and CD90^pos^ PαS ossicles, but the distribution of CD31-positive and OSX-positive cells is much more organized in ossicles derived from CD90^pos^ PαS than in the ones using unfractionated PαS ([Figure 7](#fig7){ref-type="fig"}D). This correlates well with the larger and well-structured bone marrow compartment observed in CD90^pos^ PαS ossicles, which are reminiscent of bone organoids ([Figure 7](#fig7){ref-type="fig"}C). In contrast, fewer OSX-positive and no CD31-positive cells are detected in CD90^neg^ PαS explants ([Figure 7](#fig7){ref-type="fig"}D). These observations, together with the presence of a large number of SOX9-positive cells ([Figure S4](#mmc1){ref-type="supplementary-material"}), suggests that endochondral ossification was arrested at an early step during remodeling of CD90^pos^ PαS implants.

To determine whether the endothelial and OSX-positive cells were derived from implant or host, we isolated CD90^pos^ PαS cells from newborn mice expressing DsRed ubiquitously ([@bib42]) and used them to generate cartilage constructs for implantation ([Figure 7](#fig7){ref-type="fig"}A). After 8 weeks, explants were analyzed by immunofluorescence. Donor-derived DsRed-positive cells are located in the compact bone and in the bone marrow in close contact with host-derived endothelial and hematopoietic cells ([Figure 7](#fig7){ref-type="fig"}E). In contrast, all hematopoietic (CD45) and endothelial (CD31) cells lack DsRed, which establishes that they are recruited from the host ([Figure 7](#fig7){ref-type="fig"}E). Further analysis of the hematopoietic compartment showed that CD45^pos^ cells encompass descendants of the common myeloid (granulocytes Gr1^pos^) and common lymphoid progenitors (immature and mature B cells detected by B220, [Figure 7](#fig7){ref-type="fig"}F). Rare CD45 SCA-1 double-positive cells are detected near the endosteum, which is indicative of multipotent hematopoietic progenitors ([@bib37]). Our results establish that expanding PαS CD90^pos^ shortly in culture and differentiating them in 3D COL1 matrices results in cartilage constructs that are very efficiently remodeled into bone organoids *in vivo* ([Figure 7](#fig7){ref-type="fig"}C). In particular, the engrafted constructs attract host-derived endothelial cells to establish angiogenesis and generate a niche to recruit and maintain host-derived multipotent HSCs for hematopoiesis ([Figures 7](#fig7){ref-type="fig"}D--7G).

Discussion {#sec3}
==========

Flow-cytometric analysis was used to study the ontogeny of different mesenchymal progenitor populations during mouse limb and long bone development and homeostasis. We show that the majority of Lin^neg^ mesenchymal cells during embryonic limb and fetal long bone are PαCD51 cells ([@bib33]), while their numbers drop drastically after birth. A small fraction of *Prx1-*expressing PαCD51 cells persists into adulthood. This is in support of PαCD51 cells retaining progenitor characteristics. Most importantly, PαCD51 cells encompass at least three distinct cell populations: PαS cells ([@bib25]), CD200^pos^ cells that contain all mSSCs ([@bib8]), and at least one additional population, SCA-1^neg^CD200^neg^ PαCD51 cells. These PαCD51DN cells express the highest levels of *Cxcl12*, which indicates that they might encompass/correspond to the adipo-osteogenic CAR progenitors needed for maturation of B lymphocytes ([@bib13], [@bib28], [@bib39]). This is in line with the recent observation that CAR cells are derived from the PαS population ([@bib15]) and the fact that human PαCD51 cells isolated from fetal bone marrow are self-renewing, possess multi-lineage potential, and provide HSC niche functions ([@bib33]). In addition, the different mesenchymal cell populations express *Lepr*, which is interesting as *Lepr*-positive mesenchymal progenitors are a main source of bone formed by adult bone marrow ([@bib45]). Finally, we show that the most abundant stromal cells from adult bones are Pα cells. However, as these Pα-positive cells neither express *Prx1* nor any of the other osteo-chondrogenic markers analyzed in a robust manner, they likely correspond to fibroblasts given their poor survival in culture (G.N. and R.Z., unpublished data).

Our results establish the SCA-1^pos^ PαS and the CD200^pos^ mSSCs are mutually exclusive mesenchymal progenitors with distinct developmental origins. Within the PαCD51 mesenchymal progenitors, SCA-1^pos^ cells are detected much earlier than CD200^pos^ cells in mouse limb buds. Others have proposed that the CD200^pos^ mSSCs are related to the progenitors that participate in endochondral bone formation during limb bud development, postnatal bone growth, and fracture healing ([@bib6], [@bib8], [@bib38], [@bib44], [@bib46]). In contrast, the *Sca-1*-expressing mesenchymal progenitors are detected in early limb buds surrounding the chondrogenic anlagen. Contrary to bulk of limb bud mesenchymal progenitors, SCA-1^pos^ cells are not significantly expanded prior to the onset of endochondral ossification (G.N. and R.Z., unpublished data). After birth, PαS cells continue to express *Prx1* and low levels of *Cxcl12* and *Lepr*, but not *Col2a1*, *Mmp13*, and *Osx* ([@bib13], [@bib25], [@bib31]). At this stage it is unclear whether the SCA-1^pos^ progenitors present in early mouse limb buds give rise to definitive PαS cells.

We also show that PαS cells are not homogeneous, but consist of four subpopulations that become apparent during the onset of endochondral ossification. The highest numbers of PαS cells are detected perinatally and in newborn mice; coinciding with abundant chondrogenic and osteogenic activity, peak of endothelial cell numbers, and migration of fetal HSCs from liver to bone marrow ([@bib30], [@bib41]). While all four subpopulations display CFU-F frequencies similar to that of the parental PαS population ([@bib25]), they cannot be extensively expanded in culture (this study). In agreement with the major chondrogenic activity during embryonic and early postnatal long bone development, the two CD90^neg^ subpopulations represent the bulk of PαS cells during this period and possess the best tri-lineage differentiation potential *in vitro*. Therefore, it was unexpected that CD90^neg^ PαS cartilage constructs are not remodeled into bone organoids, but appear arrested at an early stage. This suggests that 3D cartilage constructs generated from CD90^neg^ PαS either lack osteogenic progenitors and/or that chondrogenesis did not progress to hypertrophy, which is necessary to trigger endochondral ossification ([@bib21]).

The ratio between CD90^neg^ and CD90^pos^ cells reverses in long bones around 2 weeks after birth as the CD90^pos^ PαS subpopulation becomes predominant. This switch occurs as the migration of HSCs is complete and bone marrow homeostasis is achieved ([@bib41]). CD90^pos^ PαS cells initiate, but do not complete tri-lineage differentiation in 2D culture, while seeding into 3D COL1 matrices results in efficient cartilage production. Most strikingly, CD90^pos^ PαS cells have the highest CFU-F potential in culture, and cartilage constructs derived from these cells are efficiently remodeled into bone organoids *in vivo*. These bone organoids contain a well-structured marrow with a host-derived hematopoietic and vascular system. In particular, donor-derived OSX^pos^ cells resembling perinatal mesenchymal stromal progenitors ([@bib19], [@bib23], [@bib24], [@bib31]) are present in proximity to host-derived endothelial and hematopoietic cells. Most importantly, rare CD45^pos^SCA-1^pos^ cells are detected close to the endosteum, indicating that they correspond to short-term self-renewing HSCs. These findings agree with previous studies showing that PαS cells are required to maintain long-term self-renewing HSCs ([@bib13], [@bib15], [@bib25]).

Our study defines the emergence and relationships among the most relevant MSC-like populations in mice. In addition, we identify distinct PαS subpopulations and show that one of them, the CD90^pos^ PαS subpopulation, has the potential to differentiate into cartilage that is remodeled into bone organoids with a functional marrow in mice. As mouse PαS cells are contained within the PαCD51 population, our study could pave the way to identify the orthologous cells in humans, which may have important therapeutic implications for cartilage and bone tissue engineering and their co-transplantation with HSCs in human patients.

Experimental Procedures {#sec4}
=======================

A detailed description of all procedures is included in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Mouse Strains {#sec4.1}
-------------

All studies using mice were performed strictly in adherence with Swiss law, the 3R principles, and the Basel Declaration. All animal studies were approved by the cantonal animal welfare and ethics committee (licenses no. 1951 to R.Z. and no. 1797 to I.M.). Personnel performing animal studies are trained and licensed according to FELASA standards. The persons performing surgery (subcutaneous implantation) have been specially trained. Unless indicated otherwise, mice of both sexes were used for analysis. The *Prx1-*Cre ([@bib20]), DsRed (mouse strain generated using DsRed.T3-expressing embryonic stem cells; [@bib42]), inducible *β-Act-*GFP ([@bib16]), and *Sox9*^IRES-EGFP^ (Sox9-GFP, [@bib9]) mouse strains were kept in a C57BL/6J genetic background. C57BL/6 and CD1 nude mice were purchased from Janvier and Charles River Laboratories, respectively.

Isolation of Mesenchymal Cells from Limb Buds and Long Bones for Flow-Cytometric Analysis {#sec4.2}
-----------------------------------------------------------------------------------------

Cell suspensions were prepared from mouse embryonic limb buds and long bones for flow-cytometry analysis and sorting as described by [@bib14]. The modifications necessary to adapt the protocol to the different developmental stages analyzed are described in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Subcutaneous Engraftment of 3D Cartilage Scaffolds {#sec4.3}
--------------------------------------------------

PαS and CD90^pos^ and CD90^neg^PαS subpopulations were sorted by flow cytometry from mouse hindlimb long bones at postnatal day 2 (P2) and expanded *in vitro* for 5--7 days under normoxic conditions (21% O~2~, 5% CO~2~; [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}). Then 100,000 cells (20,000 cells/μL) were seeded per COL1-matrix (Avitene Ultrafoam Collagen Sponge; C.R. Bard, USA) and cultured in expansion medium overnight. Half of the matrices were continuously cultured in expansion medium to serve as controls, while the others were cultured in chondrogenic differentiation medium for 7 days ([Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}). After this, one set of COL1-constructs per cell type was used for histological analysis by Von Kossa staining, Safranin O staining, and immunofluorescence. The others were subcutaneously implanted into adult nude CD1 mice (weeks 12--15) as previously described ([@bib36]). Constructs were retrieved 8 weeks later and analyzed by histology and immunofluorescence ([Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"} and [@bib35]).
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